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ABSTRACT
Introduction Self- directed and interpersonal violence 
among people with severe mental illness has become a 
health priority. Though non- pharmacological interventions 
have been investigated, to our knowledge, no summary 
of all systematic reviews on this topic has been reported. 
We will conduct a rapid overview of reviews to synthesise 
evidence available by identifying systematic reviews on 
non- pharmacological interventions for self- directed or 
interpersonal violence in people with severe mental illness.
Methods and analysis This is a protocol for a rapid 
overview of reviews. The overview will include any 
systematic reviews (with or without meta- analyses) of 
randomised controlled trials (RCTs) or cluster RCTs that 
examine the effect of non- pharmacological interventions 
on self- directed or interpersonal violence in people with 
severe mental illness. This protocol applies the Preferred 
Reporting Items for Systematic Review and Meta- 
Analysis (PRISMA) Protocols, the criteria for conducting 
overviews of reviews in the Cochrane Handbook of 
Systematic Reviews of Interventions and the criteria for 
the Cochrane Rapid Reviews. To identify studies, a search 
will be performed in the following databases: PubMed, 
EMBASE, PsycINFO, CINAHL, LILACS, SciELO, Web of 
Science, Scopus, ProQuest, the Cochrane Database of 
Systematic Reviews through the Cochrane Library and 
the Epistemonikos database of systematic reviews. The 
searches date from inception to September 2020. The 
study selection process will be described using a PRISMA 
flow diagram, we will assess the quality of evidence 
in systematic reviews included and the quality of the 
systematic reviews themselves and the main results will 
be summarised in categories to provide a map of the 
evidence available.
Ethics and dissemination No patients or other 
participants will be involved in this study. The results 
will be presented at mental health conferences and for 
publication in a peer- reviewed journal.
Registration details The protocol was registered on the 
Open Science Framework (https:// osf. io/ myzd9/).
INTRODUCTION
The prevalence of severe mental illness has 
been estimated at 3.7%–4.1% among adults 
in the USA at different time points between 
2008 and 2014.1 Individuals with severe 
mental illness ‘suffer from severe psychiatric 
disorders together with long- term mental 
disturbances, which entail a variable degree 
of disability and social dysfunction, and must 
be cared for by means of different social and 
health resources of the psychiatric and social 
healthcare network’.2 The conditions from 
the International Classification of Diseases, 
10th Revision (ICD-10) included in severe 
mental illness are: schizophrenic disorders, 
schizotypal disorders, persistent delusional 
disorders, induced delusional disorders, 
schizoaffective disorders, other non- organic 
psychotic disorders, bipolar disorder, major 
depressive episode with psychotic features, 
recurrent major depressive disorders and 
compulsive–obsessive disorder.3 4
The WHO defines violence as ‘the inten-
tional use of physical force or power, threat-
ened or actual, against oneself, another 
person, or against a group or community, 
that either results in or has a high likelihood 
of resulting in injury, death, psychological 
harm, maldevelopment, or deprivation’.5 
The risk of self- directed and interpersonal 
violence is higher in people with severe 
mental illness than the general population. 
Although suicide and violence tend to have 
been studied separately, there are similarities 
and a relationship has been found between 
Strengths and limitations of this study
 ► This research has potential usefulness for mental 
health system decision makers.
 ► This rapid overview protocol was developed con-
sidering the Cochrane criteria and additional steps 
have been included to reduce the risk of bias.
 ► It will summarise evidence from systematic reviews 
which include randomised controlled trials.
 ► As it will only include systematic reviews, there is 
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suicidal and violent behaviour in people with schizo-
phrenia.6 7 Further, there is evidence of an association 
between mental illnesses, such as schizophrenia and 
related disorders, and higher rates of convictions for 
violent offences, suicide and premature mortality.8
Nearly 8% of people with severe mental illness have 
perpetrated violence and people with mental disorders 
are over- represented in prisons, one in seven prisoners 
being diagnosed with psychosis or depression.9 10 Notably, 
patients convicted of homicide were found to have had 
symptoms of mental illness before the offence.11
Risk factors that may contribute to interpersonal 
violence in people with mental illness include: the diag-
nosis of schizophrenia, involuntary admissions, a history 
of violence substance abuse, insight, impulsiveness, 
psychopathy, motor speed, a global measure of cogni-
tion, baseline injurious violence and medication non- 
adherence.12–16 Regarding the neurobiological aetiology, 
frontal and temporal lobe abnormalities are found in 
people with schizophrenia and aggressive behaviour, and 
the anterior cingulate cortex plays an important role in 
violent behaviour in this population.17 18
On the other hand, it is important to highlight the 
stigma surrounding the perception that people with 
severe mental illness are violent.19 Further, patients with 
schizophrenia are at risk of violent and non- violent victi-
misation and violent victimisation adversely impacts the 
course of their illness.20–22 Indeed, victimisation rates are 
higher in adults with a psychotic disorder than in the 
general community, and they are more often a victim 
than perpetrator of violence.23
In an ongoing scoping review on this topic, the prelim-
inary findings indicate the use of non- pharmacological 
interventions related to self- directed or interpersonal 
violence in people with severe mental illness within 
randomised controlled trials (RCTs) but there is hetero-
geneity in interventions. Furthermore, some of these 
RCTs are included in systematic reviews.24
There are systematic reviews on non- pharmacological 
interventions in people with severe mental illness assessing 
the effect on interpersonal violence.25–30 Regarding non- 
pharmacological interventions, the treatments evaluated 
in systematic reviews include:
 ► Mental health advance directives: these allow indi-
viduals with mental illnesses to, when their condition 
allows and they are competent to do so, state their 
preferences concerning their treatment.25
 ► Crisis intervention: crisis- focused treatment of an 
acute psychiatric episode.26
 ► Cognitive remediation and social cognitive training: 
interventions focused on cognition and psychosocial 
functioning, social functioning by improving partic-
ipants’ social cognition, prosocial skills training and 
metacognitive skills.28
 ► Compulsory community and involuntary outpatient 
treatment: follow- up interventions started when a 
patient is discharged from hospital, in which the 
patient is supervised and must adhere to the treatment 
prescribed; otherwise, the health professional may 
recommend involuntary readmission.29
 ► Psychosocial interventions: covering a wide range of 
types of treatments of differing intensity and dura-
tion that seek to address patients’ problems, these 
interventions include integrated and non- integrated 
care, motivational interviewing, contingency manage-
ment, cognitive behavioural therapy (CBT), problem- 
solving therapy and skills training.30
On the other hand, the suicide risk in people with schiz-
ophrenia is estimated at 4.9% and in people with bipolar 
disorder is 20–30 times higher than in the general popu-
lation.31 32 Among this population, the common suicide 
methods are hanging, jumping from a height/in front of 
a moving vehicle and self- poisoning.11
Some of the risk factors for self- directed violence are a 
family history of suicide, comorbid substance and alcohol 
use disorder, affective symptoms, number of psychiatric 
admissions, younger age, closeness to illness onset, older 
age at illness onset and male sex.33 34 Concerning the 
neurobiology, low pregnenolone levels are found in the 
parietal cortex in people with schizophrenia and bipolar 
disorder who died by suicide, and there is evidence 
suggesting associations between the brain- derived neuro-
trophic factor Val/Met genotype and suicidal behaviour 
in people with a bipolar disorder and between inferior 
frontal white matter alterations and both suicidality and 
self- aggression in people with schizophrenia.35–37
Systematic reviews have been carried out to assess the 
effect of non- pharmacological treatments on self- directed 
violence in people with severe mental illness.25 26 30 38–42 
Treatments evaluated in these reviews include:
 ► Community mental health team treatment: a multidis-
ciplinary community- based team which provides care 
management.38
 ► Intensive case management: community- based long- 
term care for people who do not require immediate 
admission.40
 ► CBT: a psychosocial treatment to help people with 
distressing emotional experiences or dysfunctional 
behaviour and re- evaluate their appraisals of their 
experiences.41
 ► Peer support: a recovery- oriented approach that 
allows people with experiential knowledge of mental 
illness to give appraisal, emotional and informational 
support to other patients.42
An umbrella review was performed of interventions 
in general and forensic psychiatry on violence preven-
tion.43 Nonetheless, this review is not focused on severe 
mental illness, it does not include self- directed violence, 
the intervention studies included non- randomised as 
well as randomised controlled designs, and the search 
period was until August 2015, and hence, it does not 
consider more recently published studies such as those of 
Kisely et al, Hunt et al, Dieterich et al, Jones et al.29 30 40 41 
No similar overviews have been found related to non- 
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RATIONALE
The strategies for interpersonal and self- directed violence 
in people with severe mental illness vary across systematic 
reviews. For this reason, it is important to summarise the 
knowledge available concerning interventions to tackle 
this complex problem.
Although systematic reviews may help decision makers 
to interpret the published literature; this may be more 
difficult, however, when there are several of this type of 
review. As their number grows, an overview of systematic 
reviews makes it possible to summarise the evidence on a 
specific topic.44 Notwithstanding the existence of several 
systematic reviews, no overview of systematic reviews has 
been found related to non- pharmacological interven-
tions on self- directed or interpersonal violence in people 
with severe mental illness.
Considering the importance of this topic, the lack of 
a summary of all published systematic reviews, and that 
such a summary would be of the interest to healthcare 
practitioners, mental healthcare systems and policy 
makers, we will conduct a rapid overview of reviews to 
synthesise evidence available by identifying systematic 
reviews on this topic.45
OBJECTIVE
This rapid overview aims to summarise the evidence 
from systematic reviews regarding the effects of non- 
pharmacological interventions for self- directed or inter-
personal violence in people with severe mental illness in 
any setting.
REVIEW QUESTION
Which non- pharmacological interventions for self- 
directed or interpersonal violence are effective for people 
with severe mental illness?
METHODS
Protocol and registration
This protocol was drafted considering the Preferred 
Reporting Items for Systematic Review and Meta- Analysis 
Protocols (PRISMA- P) 2015 guidelines, as indicated in 
online supplemental file 1).46 This is a rapid overview; 
therefore, some elements necessary for a full overview 
of systematic reviews are simplified. Nonetheless, this 
protocol follows the criteria for conducting overviews of 
reviews in the Cochrane Handbook of Systematic Reviews 
of Interventions, and the criteria for the Cochrane Rapid 
Reviews with steps to reduce the risk of bias.47–49
The protocol has been reviewed by the research team 
and it was registered on the Open Science Framework 
(https:// osf. io/ myzd9/).
Patient and public involvement
Ethics approval is not required for this rapid overview as 
no patients will be involved in this study.
Criteria for considering reviews for inclusion
Systematic reviews will be selected using the following 
criteria.
Types of studies
We will include systematic reviews (with or without meta- 
analyses) of RCTs or cluster RCTs that examine the effect 
of non- pharmacological interventions on self- directed 
or interpersonal violence in people with severe mental 
illness. Additionally, we will include systematic reviews 
that include RCTs and non- RCT studies, if they performed 
separate analyses or data synthesis for the RCTs included.
Exclusion criteria
Publications being a systematic review in which no studies 
met the inclusion criteria, narrative reviews or clinical 
practice guidelines that do not meet the definition of a 
systematic review.45
The systematic review criteria to guide the decision to 
include studies are45 50 51:
 ► A priori specification of a research question.
 ► Systematic, explicit and reproducible methodology 
(eligibility criteria, information sources, search, study 
selection, data collection process and so on).
 ► Acceptable methods for assessing studies.




Reviews must include adults with a diagnosis of severe 
mental illness or any condition included in severe mental 
illness3: schizophrenic disorder, schizoaffective disorder, 
schizotypal disorder, persistent or induced delusional 
disorder, bipolar disorder, obsessive- compulsive disorder, 
major depressive episode with psychotic features, recur-
rent major depressive disorders, atypical psychosis or 
other non- organic psychosis (according to international 
classification systems: Diagnostic and Statistical Manual 
of Mental Disorders or ICD). The criteria established for 
severe mental illness follow clinical practice guidelines on 
psychosocial interventions in severe mental illness3 and 
eligible methods for identifying the population include 
clinical diagnosis and research interview, among others. 
We will also include studies in adults with severe mental 
illness and substance abuse. Systematic reviews that 
include other populations not considered in this study 
will be included if they performed separate analyses or 
data synthesis for severe mental illness. No restrictions 
will be placed on the setting.
Exclusion criteria
People with substance abuse alone or with organic mental 
disorders, dementia, mental retardation or learning 
disabilities.
Types of interventions
Interventions must be non- pharmacological, in combi-
nation or not with another intervention, and for 
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interpersonal or self- directed violence in people with 
severe mental illness. Violence should be established in 
accordance with the WHO definition.5 There will be no 
restrictions regarding the duration, frequency, provider 
or timing of the interventions.
Interventions may be:
 ► Direct: if they affect patients.
 ► Indirect: if their influence is not on patients, but is to 
their benefit.
 ► Targeting family, professionals or the community or at 
a public health level.
Exclusion criteria
Instrumental treatments or brain stimulation treatments 
such as electroconvulsive therapy, transcranial direct 
current stimulation or transcranial magnetic stimulation.
Concomitant pharmacological treatments will be 
allowed if they are administered in the same way in all 
study groups (intervention and control groups).
Comparisons of interest
Another treatment, placebo or treatment as usual (the 
usual treatment being defined as the normal level of 
care provided in the area in which the study has been 
performed).
Types of outcomes
The outcomes of interest are:
Main outcomes:
 ► Violent behaviour:
 – Interpersonal violence: physical or verbal aggres-
sion, physical or verbal threats, psychological or 
emotional abuse, criminal activity or behaviour 
(major offences or felony), arrest for violence, as-
sault or property damage.
 – Self- directed violence: suicide attempt, completed 
suicide or self- harm.
Additional outcomes:
 ► Disruptive or agitation behaviour.
 ► Homicidal ideation.
 ► Suicide ideation or thoughts, suicide plans.
 ► Substance use: drug use or alcohol use.
 ► Global, mental and emotional state:




 – Well- being, quality of life and life satisfaction.
 – Insight.




 ► Health service and treatment:
 – Admissions and discharges.
 – Contacts with mental health services.
 – Use of physical restraints or seclusion.
 – Use of medication.
 – Compliance.
 – Satisfaction with service or care.
 ► Justice system or police contacts:
 – Offences (minor or less serious offences).
 – Arrests.
 – Drug- related crimes.
 – Convictions (minor or less serious convictions).
 – Incarcerations.
 ► Economic costs:
 – Direct or indirect costs.
 ► Adverse events/effects: any general adverse effects or 
specific adverse effects.
 ► Leaving the study early.
Search methods for identification of reviews
We will search the following databases for Cochrane inter-
vention reviews and non- Cochrane systematic reviews: 
PubMed, EMBASE, PsycINFO, CINAHL, LILACS, 
SciELO, Web of Science, Scopus, ProQuest, the Cochrane 
Database of Systematic Reviews (CDSR) through the 
Cochrane Library and the Epistemonikos database of 
systematic reviews. We will use search terms, MeSH head-
ings and search filters specific to the systematic review 
or meta- analysis study design.45 We have developed the 
initial search strategy for the PubMed database (online 
supplemental file 2) and will adapt it, as appropriate, 
for other databases. We will not apply language or date 
restrictions. We will use RefWorks software to manage the 
references.52
Selection of reviews
One author (MCM- C) will search all of the reviews and will 
remove any which are not relevant based on the title. If 
the search of the CDSR retrieves protocols or a Cochrane 
review is not up to date, we will contact the author team or 
review group to ask whether a pre- publication version of 
the study or an updated review is available.45 If only some 
of the primary studies within systematic reviews meet the 
rapid overview’s inclusion criteria, we will include these 
subsets of primary studies in the rapid overview.45
Title and abstract screening
We will conduct a pilot exercise using 30–50 abstracts to 
calibrate and test the review form. To identify the relevant 
reviews, two reviewers (FJB- R, MCM- C) will conduct dual 
screening of at least 20% of abstracts and one of them 
(MCM- C) will screen the remaining titles and abstracts, 
while the second reviewer (FJB- R) will screen all abstracts 
excluded.48
Full-text screening
Similarly, we will conduct a pilot test using 5–10 full- text 
articles to calibrate and test the review form. Then, one 
reviewer (MCM- C) will screen all the full texts retrieved 
and included to assess them for final inclusion/exclusion 
and the second reviewer (FJB- R) will screen all full- text 
articles excluded.48
Any disagreements will be resolved by discussion and 
consensus. We will use Covidence or Rayyan software 
copyright.
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programmes to manage the study selection process.53 54 
We will summarise the process of the study selection using 
a PRISMA flow diagram.51
Managing systematic review and primary study overlap
One author (MCM- C) will investigate potential overlap of 
primary studies between the systematic reviews included. 
Any overlap detected will be presented as a citation matrix 
and/or as a Venn diagram.45
Further, if overlap is identified, two researchers (FJB- 
R, MCM- C) will use the information and methodological 
quality of each review to reach an agreement concerning 
which data from which review to include within the rapid 
overview. In brief, the following will be included: all non- 
overlapping systematic reviews, and among groups of 
overlapping reviews, the Cochrane systematic review, the 
most recent, the highest quality, the most relevant or the 
most comprehensive systematic reviews.45
Data extraction and analysis
One reviewer (MCM- C) will perform data extraction for 
each review using a predefined data extraction form and 
a second reviewer (FJB- R) will check data extracted for 
correctness and completeness.48 The descriptive charac-
teristics of each systematic review and their primary studies 
will be extracted and reported. The information will be 
classified under the following categories: author(s), year 
of publication, country of publication, review title, regis-
tration details of the review protocol, number of studies 
included, design of primary studies included, study popu-
lation, setting, description of the intervention and the 
control conditions, outcomes and details of key findings, 
and methodological quality of the studies.45
Any reasons for data missing from systematic reviews 
will be recorded. To deal with missing or unclear data, the 
individual trials included in the reviews will be assessed or 
the author of the original paper contacted.
Assessment of methodological quality of reviews included
We will assess the quality of evidence in systematic 
reviews included and the quality of the systematic reviews 
themselves:
Quality of evidence in reviews included
One author (MCM- C) will extract and report Grading of 
Recommendations Assessment, Development and Eval-
uation (GRADE) assessments presented in the reviews, 
if available. These assessments will be presented in the 
‘Summary of Findings’ tables according to the GRADE 
and recommendations in the Cochrane Handbook for 
Systematic Reviews of Interventions.47 55 The GRADE 
instrument grades the quality of evidence and the strength 
of recommendations, and it has four levels of evidence 
(high, moderate, low and very low quality).56
Quality of reviews included
The revised measurement tool to assess systematic reviews 
(AMSTAR-2) will be used to assess the quality of the 
reviews included by the first reviewer, with full verification 
of all judgements (and support statements) by the second 
reviewer. The instrument includes 16 items to evaluate 
quality dimensions and provide a rating for overall confi-
dence in the results of a review as ‘high’, ‘moderate’, ‘low’ 
or ‘critically low’.57
Data synthesis and reporting of findings
Narrative summaries of the data included in each system-
atic review will be presented in a ’Summary of findings’ 
table as recommended in the Cochrane Handbook for 
Systematic Reviews of Interventions, including a summary 
of the quality of evidence.45 47 The data will be reported as 
they are presented in the systematic reviews included.45 If 
the studies included in the systematic reviews are pooled, 
the effect estimates, 95% CIs and measures of heteroge-
neity will be extracted.45
To provide a map of the available evidence, the main 
results will be summarised into categories45 58:
 ► Effective interventions: there is evidence of effective-
ness for an intervention.
 ► Promising interventions: there is some evidence of 
effectiveness for an intervention; however, more 
evidence is needed.
 ► Ineffective interventions: there is evidence of lack of 
effectiveness for an intervention.
 ► Probably ineffective interventions: there is evidence 
suggesting a lack of effectiveness for an intervention; 
however, more evidence is needed.
 ► No conclusions possible due to lack of evidence: 
there is insufficient evidence on the effectiveness of 
an intervention.
The selection of category will reflect the conclusions of 
the authors of the reviews included.58
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